[1] [1] LI Z, HOSHINO Y, TRAN L,et al. Phylogenetic articulation of uric acid evolution in mammals and how it informs a therapeutic uricase [J].Mol Biol Evol, 2022,39(1): msab312.

[2] [2] HUANG Z, XIE N, ILLES P,et al. From purines to purinergic signalling: molecular functions and human diseases[J].Signal Transduct Target Ther, 2021,6(1): 162.

[3] [3] CAI L M, LI Q, DENG Y B,et al. Construction and expression of recombinant uricase-expressing genetically engineered bacteria and its application in rat model of hyperuricemia [J].Int J Mol Med, 2020,45(5): 1488-1500.

[4] [4] SCHLESINGER N, PREZ-RUIZ F, LIOT F. Mechanisms and rationale for uricase use in patients with gout [J].Nat Rev Rheumatol, 2023,19(10): 640-649.

[5] [5] F D A. Krystexxa(pegloticase) injection for intravenous infusion [EB/OL]. [2024-12-03]. https://fda.report/media/79472/Krystexxa-Medication-Guide.pdf.

[6] [6] MANDAL A K, MOUNT D B. The molecular physiology of uric acid homeostasis [J].Annu Rev Physiol, 2015,77: 323-345.

[7] [7] PIERZYNOWSKA K, DESHPANDE A, MOSIICHUK N,et al. Oral treatment with an engineered uricase, ALLN-346, reduces hyperuricemia, and uricosuria in urate oxidasedeficient mice [J].Front Med(Lausanne), 2020,7: 569215.

[8] [8] TANG Y K, DU Y W, YE J N,et al. Intestine-targeted explosive hydrogel microsphere promotes uric acid excretion for gout therapy [J].Adv Mater, 2024,36(3): e2310492.

[9] [9] ZHAO R, LI Z M, SUN Y Q,et al. EngineeredEscherichia coliNissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment [J].Gut Microbes, 2022,14(1): 2070391.

[10] [10] MACKENZIE D A, TAILFORD L E, HEMMINGS A M,et al. Crystal structure of a mucus-binding protein repeat reveals an unexpected functional immunoglobulin binding activity[J].J Biol Chem, 2009,284(47): 32444-32453.

[11] [11] ETZOLD S, KOBER O I, MACKENZIE D A,et al. Structural basis for adaptation of lactobacilli to gastrointestinal mucus [J].Environ Microbiol, 2014,16(3): 888-903.

[12] [12] ROOS S, JONSSON H. A high-molecular-mass cell-surface protein fromLactobacillus reuteri1063 adheres to mucus components [J].Microbiology(Reading), 2002,148(Pt 2): 433-442.

[14] [14] WANG Y, LU J, HUANG Z,et al. Process development of recombinantAspergillus flavusurate oxidase production inPichia pastorisintracellularly and its characterization as a potential biosimilar [J].Process Biochem, 2021,102: 376-385.

[15] [15] MARCUS R, NIKKI D, MOULAY HICHAM A I. Mucinbinding fusion proteins: US, 20210246176A1 [P]. 2021-08-12.